AbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus
(Thomson Reuters ONE) -
VANCOUVER, British Columbia, Jan. 20, 2016 (GLOBE NEWSWIRE) --
AbCellera announced today successful completion of its first antibody discovery
partnership with MassBiologics of the University of Massachusetts Medical
School. The project, funded by the Defense Advanced Research Project Agency
(DARPA) under the ADEPT-PROTECT program, was directed towards rapid human
antibody discovery for infectious diseases.
Through this collaboration AbCellera demonstrated single cell antibody discovery
with throughput of millions of cells per experiment, allowing for the efficient
and deep screening of natural antibody responses from patients following
infection or challenge. Using AbCellera's platform, the selection and sequencing
of fully human antibodies was achieved in as little as five days. Screening of
over 10 million single B cells was used to discover a panel of hundreds of
ultra-rare antibodies against multiple targets from enterotoxigenic Escherichia
coli. In a separate element of the collaboration, AbCellera also identified
hundreds of human anti-Ebola antibodies from a single blood sample obtained from
a convalescent human patient, and provided sequences of a select subset of
antibodies in less than a week.
Dr. Carl Hansen, CEO and co-founder of AbCellera commented: "We are very pleased
with the success of this project, which has clearly established our platform as
a powerful approach for human antibody discovery. In particular, our data has
demonstrated single cell antibody screening with combined speed, throughput and
assay flexibility that is unmatched. In addition to infectious diseases, these
capabilities are enabling for applications in immuno-oncology, and will open new
opportunities for rapid functional profiling of human immune responses."
This work was made possible by close collaboration between team members from
AbCellera and MassBiologics within the frame of the ADEPT-PROTECT program. "We
would like to thank Dr. Mark Klempner for his leadership in this project, as
well as Drs. Colby Souders, William Thomas, Yang Wang, Keith Reimann, Lisa
Cavacini, and the larger MassBiologics scientific team. Their efforts have made
this both a very enjoyable and a productive partnership. We are grateful for
DARPA's support and it has been an honor to be of service in this important and
forward-looking initiative led by Colonel Dan Wattendorf to bolster rapid
pandemic response and biodefense." said Dr. Hansen.
For more information on AbCellera and potential partnership opportunities,
please visit www.abcellera.com or contact:
Kevin Heyries
Telephone: 604-827-4151
Email: media(at)abcellera.com
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling
technologies for the discovery and development of monoclonal antibody (mAb)
therapies directly from natural immune cells.
AbCellera's lead technology is a proprietary single cell antibody discovery
platform that provides pharma and biotech partners with the ability to rapidly
identify mAb therapeutic candidates from the natural immune repertoires of any
species, including humans. For more information, please visit www.abcellera.com
About MassBiologics
MassBiologics of the University of Massachusetts Medical School is the only
publicly owned, non-profit FDA-licensed manufacturer of vaccines and other
biologic products in the United States. The laboratory was established in 1894
by the state Board of Health to produce diphtheria antitoxin. Since that time,
the focus at MassBiologics has been to improve public health through applied
research, development and production of biologic products. In 1997, the
Commonwealth of Massachusetts transferred MassBiologics operations from the
Department of Public Health to UMass Medical School to "maintain their public
purpose, preserving their ability to compete in an increasingly competitive
marketplace and to maximize their value to the Commonwealth."
About the University of Massachusetts Medical School
The University of Massachusetts Medical School has built a reputation as a
world-class research institution, consistently producing noteworthy advances in
clinical and basic research. The Medical School attracts more than $270 million
in research funding annually, 80 percent of which comes from federal funding
sources. The mission of the Medical School is to advance the health and well-
being of the people of the commonwealth and the world through pioneering
education, research, public service and health care delivery with its clinical
partner, UMass Memorial Health Care. For more information,
visit http://www.umassmed.edu/.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AbCellera via GlobeNewswire
[HUG#1980317]
Datum: 21.01.2016 - 01:34 Uhr
Sprache: Deutsch
News-ID 445526
Anzahl Zeichen: 5857
contact information:
Town:
Vancouver
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCellera Announces Successful Completion of Collaboration for the Discovery of Fully Human Antibodies Against Pathogenic E. Coli and Ebola Virus"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCellera (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
